Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)

H. A. Ghofrani, F. Grimminger, M. M. Hoeper, N. H. Kim, E. Mayer, G. Simonneau, M. Sikirica, A. Fritsch, N. Davie, B. Luong, M. R. Wilkins (Giessen, Hannover, Bad Nauheim, Berlin, Wuppertal, Germany; San Diego, United States Of America; Le Kremlin-Bicêtre, France; London, United Kingdom)

Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Session: Pulmonary circulation: clinical science and treatment
Session type: Poster Discussion
Number: 3418
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. A. Ghofrani, F. Grimminger, M. M. Hoeper, N. H. Kim, E. Mayer, G. Simonneau, M. Sikirica, A. Fritsch, N. Davie, B. Luong, M. R. Wilkins (Giessen, Hannover, Bad Nauheim, Berlin, Wuppertal, Germany; San Diego, United States Of America; Le Kremlin-Bicêtre, France; London, United Kingdom). Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Respir J 2013; 42: Suppl. 57, 3418

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013


Quality of life and physical functioning in chronic thromboembolic pulmonary hypertension (CTEPH):  the impact of treatment
Source: International Congress 2017 – PAH and CTEPH
Year: 2017


Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013

Sildenafil improves health-related quality of life in pulmonary arterial hypertension (PAH) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 563s
Year: 2005

Relationship of quality of life and life expectancy with tolerance to physical exercises and cardio respiratory parameters in patients with pulmonary arterial hypertension
Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases
Year: 2013

Quality of life in patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2016; 48: 526-537
Year: 2016



EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013


Relation of the novel pulmonary hypertension emPHasis10 quality of life score to markers of disease severity
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015


Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009


Health-related quality of life in patients with pulmonary arterial hypertension
Source: Annual Congress 2011 - Clinical features of pulmonary hypertension
Year: 2011

The influence of psycho-social factors in the evolution of pulmonary hypertension patients
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013

Measurement of quality of life in pulmonary hypertension and its significance
Source: Eur Respir J 2006 Oct 01;28(4):808-815
Year: 2006



Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH)
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014

Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)
Source: Eur Respir J 2010; 35: 118-123
Year: 2010



Nutritional status and health-related quality of life in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 484s
Year: 2001

Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study
Source: ERJ Open Res, 7 (3) 00617-2020; 10.1183/23120541.00617-2020
Year: 2021



The assessment of life expectancy of patients with primary pulmonary hypertension (PPH)
Source: Eur Respir J 2003; 22: Suppl. 45, 582s
Year: 2003

Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study)
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013


Predictors of health-related quality of life in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 66s
Year: 2006

Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year
Source: Eur Respir J 2010; 35: 1022-1030
Year: 2010